Central Trust Company’s Mural Oncology MURA Stock Holding History

Central Trust Company’s Portfolio MURA Stock Details MURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9	Closed	-$45	–	1437
2024 Q1	$45	Hold	9	–	–	﹤0.01%	1365
2023 Q4	$54	Buy	+9	New	+$36	﹤0.01%	1373

Other funds holding MURA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Central Trust Company's MURA Position: Q2 2024 in Review

Central Trust Company sold out of Mural Oncology (MURA) in Q2 2024, closing a stake of 9 shares — an estimated $45 sold.

Central Trust Company first reported a position in MURA in Q4 2023 and held it in 2 quarters. The position peaked at $54 in Q4 2023. 86 funds tracked by Wall St. Rank hold MURA as of Q2 2024.

Central Trust Company reported no remaining Mural Oncology position as of Q2 2024 after selling out during the quarter.
Central Trust Company sold 9 Mural Oncology shares in Q2 2024, an estimated $45.
Central Trust Company first reported a position in Mural Oncology in Q4 2023 and held it in 2 quarters.
Central Trust Company's Mural Oncology position peaked at $54 in Q4 2023.
86 funds tracked by Wall St. Rank held Mural Oncology as of Q2 2024.

Based on Central Trust Company's 13F filing for Q2 2024, filed 5 Aug 2024.